CDKN1B and prostate carcinoma: AKT is activated in 50% of breast and prostate cancers and promotes tumorigenesis by teaming with 14-3-3 to regulate key proteins involved in cellular transformation, such as FoxO transcription factors, the pro-apoptotic protein BAD and the cell cycle regulator p27Kip1 among others.